Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALBT NASDAQ:SCYX NASDAQ:TENX NASDAQ:XFOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBTAvalon GloboCare$2.23-0.5%$2.33$1.87▼$11.66$8.56M0.03262,439 shs33,374 shsSCYXSCYNEXIS$0.78+2.7%$0.90$0.66▼$1.60$32.49M1.68232,772 shs256,385 shsTENXTenax Therapeutics$6.79+1.6%$6.52$3.90▼$8.24$30.94M1.5841,786 shs19,110 shsXFORX4 Pharmaceuticals$3.05+2.7%$3.29$1.35▼$26.83$34.80M0.541.45 million shs366,961 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBTAvalon GloboCare0.00%-0.88%-16.73%-3.45%-17.04%SCYXSCYNEXIS0.00%-2.00%-32.63%+6.06%-52.84%TENXTenax Therapeutics0.00%-10.46%+4.21%+12.65%+69.11%XFORX4 Pharmaceuticals0.00%-3.88%-6.31%+94.12%-80.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBTAvalon GloboCare$2.23-0.5%$2.33$1.87▼$11.66$8.56M0.03262,439 shs33,374 shsSCYXSCYNEXIS$0.78+2.7%$0.90$0.66▼$1.60$32.49M1.68232,772 shs256,385 shsTENXTenax Therapeutics$6.79+1.6%$6.52$3.90▼$8.24$30.94M1.5841,786 shs19,110 shsXFORX4 Pharmaceuticals$3.05+2.7%$3.29$1.35▼$26.83$34.80M0.541.45 million shs366,961 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBTAvalon GloboCare0.00%-0.88%-16.73%-3.45%-17.04%SCYXSCYNEXIS0.00%-2.00%-32.63%+6.06%-52.84%TENXTenax Therapeutics0.00%-10.46%+4.21%+12.65%+69.11%XFORX4 Pharmaceuticals0.00%-3.88%-6.31%+94.12%-80.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALBTAvalon GloboCare 1.00SellN/AN/ASCYXSCYNEXIS 1.00SellN/AN/ATENXTenax Therapeutics 2.83Moderate Buy$18.00169.46% UpsideXFORX4 Pharmaceuticals 2.50Moderate Buy$34.171,050.39% UpsideCurrent Analyst Ratings BreakdownLatest ALBT, TENX, XFOR, and SCYX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025SCYXSCYNEXISWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/14/2025TENXTenax TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ALBTAvalon GloboCareWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025XFORX4 PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ALBTAvalon GloboCareWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SCYXSCYNEXISWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TENXTenax TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025XFORX4 PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/8/2025TENXTenax TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.008/29/2025XFORX4 PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $9.008/14/2025TENXTenax TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$15.00 ➝ $14.00(Data available from 10/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALBTAvalon GloboCare$1.33M6.47N/AN/A($11.37) per share-0.20SCYXSCYNEXIS$3.75M8.44N/AN/A$1.45 per share0.52TENXTenax TherapeuticsN/AN/AN/AN/A$26.99 per shareN/AXFORX4 Pharmaceuticals$2.56M13.24N/AN/A$3.90 per share0.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALBTAvalon GloboCare-$7.90M-$19.96N/A∞N/A-1,451.94%N/A-75.12%11/11/2025 (Estimated)SCYXSCYNEXIS-$21.29M-$0.40N/A15.09N/A-599.05%-43.04%-28.21%11/5/2025 (Estimated)TENXTenax Therapeutics-$17.60M-$0.92N/AN/AN/AN/A-31.34%-30.39%11/12/2025 (Estimated)XFORX4 Pharmaceuticals-$37.45M-$14.84N/AN/AN/A-311.15%-375.31%-72.87%11/12/2025 (Estimated)Latest ALBT, TENX, XFOR, and SCYX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025TENXTenax Therapeutics-$1.33N/AN/AN/AN/AN/A11/12/2025Q3 2025XFORX4 Pharmaceuticals-$0.87N/AN/AN/AN/AN/A11/5/2025Q3 2025SCYXSCYNEXIS-$0.21N/AN/AN/AN/AN/A8/14/2025Q2 2025ALBTAvalon GloboCareN/A-$2.02N/A-$6.22N/A$0.35 million8/13/2025Q2 2025SCYXSCYNEXIS-$0.23-$0.14+$0.09-$0.14$0.15 million$1.36 million8/13/2025Q2 2025TENXTenax Therapeutics-$0.50-$0.27+$0.23-$0.27N/AN/A8/8/2025Q2 2025XFORX4 Pharmaceuticals-$4.53-$3.47+$1.06-$3.47$1.62 million$1.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALBTAvalon GloboCareN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/ATENXTenax TherapeuticsN/AN/AN/AN/AN/AXFORX4 PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALBTAvalon GloboCareN/A0.060.06SCYXSCYNEXISN/A5.205.20TENXTenax TherapeuticsN/A41.8941.89XFORX4 Pharmaceuticals19.103.193.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALBTAvalon GloboCare1.42%SCYXSCYNEXIS54.37%TENXTenax Therapeutics1.67%XFORX4 Pharmaceuticals72.03%Insider OwnershipCompanyInsider OwnershipALBTAvalon GloboCare37.30%SCYXSCYNEXIS4.86%TENXTenax Therapeutics3.70%XFORX4 Pharmaceuticals2.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALBTAvalon GloboCare53.84 million2.41 millionNot OptionableSCYXSCYNEXIS6041.92 million39.89 millionOptionableTENXTenax Therapeutics94.56 million4.39 millionNot OptionableXFORX4 Pharmaceuticals8011.41 million11.16 millionOptionableALBT, TENX, XFOR, and SCYX HeadlinesRecent News About These CompaniesX4 Pharmaceuticals announces restructuring, 50% reduction in workforceSeptember 17, 2025 | msn.comX4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value CreationSeptember 17, 2025 | globenewswire.comX4 Pharmaceuticals files to sell 59.89M shares of common stock for holdersSeptember 11, 2025 | msn.comX4 Pharmaceuticals Announces Board Resignations and AppointmentsAugust 25, 2025 | msn.comX4 Pharmaceuticals Grants Inducement Equity Awards to New Executive OfficersAugust 15, 2025 | quiverquant.comQX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 15, 2025 | globenewswire.comX4 Pharmaceuticals Closes $85M Private Placement DealAugust 14, 2025 | theglobeandmail.comX4 Pharmaceuticals price target lowered to $3.50 from $7 at H.C. WainwrightAugust 13, 2025 | msn.comX4 Pharmaceuticals Stock Rises On Closing Of Upsized Offering, But Brokerage Lowers Price TargetAugust 13, 2025 | msn.comX4 Pharmaceuticals Announces Closing of Upsized $85 Million Private PlacementAugust 13, 2025 | globenewswire.comX4 Pharmaceuticals announces $60M financing, management changesAugust 12, 2025 | msn.comX4 Pharmaceuticals Announces $60M Equity FinancingAugust 12, 2025 | msn.comX4 Pharmaceuticals secures $60M PIPE financingAugust 12, 2025 | msn.comX4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board LeadershipAugust 12, 2025 | globenewswire.comX4 Pharmaceuticals, Inc. (XFOR) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comX4 Pharmaceuticals Inc News (XFOR) - Investing.comJuly 2, 2025 | investing.comXFOR X4 Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comX4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)June 16, 2025 | globenewswire.comX4 Pharmaceuticals Gets Fast Track Regulatory Designation for Neutropenia DrugJune 10, 2025 | marketwatch.comX4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropeniaJune 10, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALBT, TENX, XFOR, and SCYX Company DescriptionsAvalon GloboCare NASDAQ:ALBT$2.23 -0.01 (-0.49%) As of 01:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.SCYNEXIS NASDAQ:SCYX$0.78 +0.02 (+2.70%) As of 01:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Tenax Therapeutics NASDAQ:TENX$6.78 +0.11 (+1.57%) As of 01:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.X4 Pharmaceuticals NASDAQ:XFOR$3.05 +0.08 (+2.69%) As of 01:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
